Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
BIIB logo

Biogen Navigates $6.3 Billion Debt and Patent Revocations with Alzheimer's Pivot

BIIB10-KFiling Date: 2/6/2026
Biogen Inc.
Description

What this story covers

Biogen’s 2025 10-K reveals a strategic shift toward Alzheimer’s and rare diseases to counter generic erosion of its MS franchise. Despite rising taxes and patent losses, the company maintains $4.2 billion in liquidity to fund its innovative pipeline.

Story snapshot

CompanyBiogen Inc.
TickerBIIB
VariantStandard detailed
Duration12:49
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000875045-26-000013
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in